Wells Fargo & Company MN Makes New $383,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR)

Wells Fargo & Company MN purchased a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 105,769 shares of the company's stock, valued at approximately $383,000. Wells Fargo & Company MN owned approximately 0.13% of Atyr PHARMA as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC bought a new stake in shares of Atyr PHARMA during the fourth quarter worth $3,229,000. Knott David M Jr acquired a new stake in shares of Atyr PHARMA during the fourth quarter worth $1,115,000. JPMorgan Chase & Co. grew its stake in Atyr PHARMA by 467.8% during the 4th quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock valued at $646,000 after purchasing an additional 147,092 shares during the last quarter. American Century Companies Inc. acquired a new stake in Atyr PHARMA during the 4th quarter valued at approximately $319,000. Finally, Kingswood Wealth Advisors LLC purchased a new stake in Atyr PHARMA in the fourth quarter valued at $170,000. Institutional investors own 61.72% of the company's stock.

Atyr PHARMA Price Performance

Shares of NASDAQ:ATYR traded down $0.07 on Wednesday, reaching $3.16. 1,036,627 shares of the company were exchanged, compared to its average volume of 906,155. The firm has a market cap of $280.79 million, a price-to-earnings ratio of -3.36 and a beta of 0.79. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average of $3.27 and a 200-day moving average of $3.40. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. Equities analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Atyr PHARMA in a research note on Friday, March 14th. Finally, Leerink Partners began coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Atyr PHARMA currently has an average rating of "Buy" and a consensus target price of $18.60.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.